Charles River Laboratories Intl. Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.45 (market cap $14.23B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days on average.
| CRL | HYG | |
|---|---|---|
Market Cap | $14.23B | $17.89B |
Volume | 1,176,885 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $81.28 |
52-Week Low | $149.93 | $76.90 |
Typical Hold Time | 33 Days | 60 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
HYG trades at $77.205, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The ETF maintains regular dividend distributions, with recent payouts ranging from $0.38 to $0.44. Market focus remains on high-yield bond performance amid rising Treasury yields and Federal Reserve policy uncertainty.
The outlook for HYG remains challenged by persistent bond market volatility and rising interest rates. While the fund's consistent dividend payments provide income support, the bearish technical setup and macroeconomic headwinds suggest continued pressure on high-yield corporate bonds. Investors face risks from credit quality deterioration and duration exposure in a rising rate environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →